Literature DB >> 17533149

Lipooligosaccharide from Bordetella pertussis induces mature human monocyte-derived dendritic cells and drives a Th2 biased response.

Giorgio Fedele1, Ignacio Celestino, Fabiana Spensieri, Loredana Frasca, Maria Nasso, Mineo Watanabe, Maria Elena Remoli, Eliana Marina Coccia, Fabio Altieri, Clara Maria Ausiello.   

Abstract

Bordetella pertussis has a distinctive cell wall lipooligosaccharide (LOS) that is released from the bacterium during bacterial division and killing. LOS directly participates in host-bacterial interactions, in particular influencing the dendritic cells' (DC) immune regulatory ability. We analyze LOS mediated toll-like receptor (TLR) activation and dissect the role played by LOS on human monocyte-derived (MD)DC functions and polarization of the host T cell response. LOS activates TLR4-dependent signaling and induces mature MDDC able to secrete IL-10. LOS-matured MDDC enhance allogeneic presentation and skew T helper (Th) cell polarization towards a Th2 phenotype. LOS protects MDDC from undergoing apoptosis, prolonging their longevity and their functions. Compared to Escherichia coli lipopolysaccharide (LPS), the classical DC maturation stimulus, LOS was a less efficient inducer of TLR4 signaling, MDDC maturation, IL-10 secretion and allogeneic T cell proliferation and it was not able to induce IL-12p70 production in MDDC. However, the MDDC apoptosis protection exerted by LOS and LPS were comparable. In conclusion, LOS treated MDDC are able to perform antigen presentation in a context that promotes licensing of Th2 effectors. Considering these properties, the use of LOS in the formulation of acellular pertussis vaccines to potentiate protective and adjuvant capacity should be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533149     DOI: 10.1016/j.micinf.2007.03.002

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  11 in total

1.  Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway.

Authors:  Jay W Chaplin; Shinji Kasahara; Edward A Clark; Jeffrey A Ledbetter
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 2.  Pertussis vaccines and protective immunity.

Authors:  Parul Kapil; Tod J Merkel
Journal:  Curr Opin Immunol       Date:  2019-05-09       Impact factor: 7.486

3.  Immunotherapy using lipopolysaccharide-stimulated bone marrow-derived dendritic cells to treat experimental autoimmune encephalomyelitis.

Authors:  F Zhou; B Ciric; G-X Zhang; A Rostami
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Bordetella Colonization Factor A (BcfA) Elicits Protective Immunity against Bordetella bronchiseptica in the Absence of an Additional Adjuvant.

Authors:  Kacy S Yount; Jamie Jennings-Gee; Kyle Caution; Audra R Fullen; Kara N Corps; Sally Quataert; Rajendar Deora; Purnima Dubey
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

5.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

6.  Use of whole-blood samples in in-house bulk and single-cell antigen-specific gamma interferon assays for surveillance of Mycobacterium tuberculosis infections.

Authors:  Raffaella Palazzo; Fabiana Spensieri; Marco Massari; Giorgio Fedele; Loredana Frasca; Stefania Carrara; Delia Goletti; Clara M Ausiello
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

7.  GSH-C4 Acts as Anti-inflammatory Drug in Different Models of Canonical and Cell Autonomous Inflammation Through NFκB Inhibition.

Authors:  Dolores Limongi; Sara Baldelli; Paola Checconi; Maria Elena Marcocci; Giovanna De Chiara; Alessandra Fraternale; Mauro Magnani; Maria Rosa Ciriolo; Anna Teresa Palamara
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

8.  Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways.

Authors:  Giorgio Fedele; Fabiana Spensieri; Raffaella Palazzo; Maria Nasso; Gordon Yiu Chong Cheung; John Graham Coote; Clara Maria Ausiello
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

9.  Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism.

Authors:  Corinna Schnoeller; Xavier Roux; Devika Sawant; Dominique Raze; Wieslawa Olszewska; Camille Locht; Peter J Openshaw
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 30.528

10.  Bordetella bronchiseptica is a potent and safe adjuvant that enhances the antigen-presenting capability of dendritic cells.

Authors:  You-Jeong Lee; Yong Han; Hong-Gu Joo
Journal:  Korean J Physiol Pharmacol       Date:  2020-12-20       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.